Table 4.
Changes from baseline in body fat composition, glucose metabolism, and index of insulin resistance after 6 months of metformin therapy between the SLC22A1 variant and reference groups
| Median (Range) | |||
|---|---|---|---|
|
| |||
| Parameter | Reference Group (n = 18) | SLC22A1 Variant Group (n = 10) | P value |
|
| |||
| Total Fat by DEXA (g) | −429 (−9502, 2246) | 580 (−2649, 7824) | NS |
|
| |||
| Trunk Fat by DEXA (g) | −523 (−4952, −1550) | 532.500 (−844, 3351) | 0.053 |
|
| |||
| Total Fat by DEXA (%) | −1.95 (−7.00, 0.500) | −0.700 (−2.00, 8.80) | 0.053 |
|
| |||
| Trunk Fat by DEXA (%) | −2.20 (−9.00, 0.900) | −1.20 (−2.40, 7.30) | 0.035 |
|
| |||
| Abdominal adipose tissue by MRI (cc) | |||
| L2-3 subcutaneous | 8.70 (−146 – 93.8) | −12.6 (−169 – 140) | NS |
| L4-5 subcutaneous | −12.1 (−247 – 58.9) | −14.7 (−1334 – 92.5) | NS |
| L2-3 intra-abdominal | −8.60 (63.3 – 166) | −14.6 (−26.0 – 20.3) | NS |
| L4-5 intra-abdominal | −2.95 (−73.2 – 248) | −6.57 (−35.2 – 23.0) | NS |
|
| |||
| Fasting Insulin (mIU/mL) | −2.40 (−17.8, 21.5) | 0.000 (−14.0, 15.1) | NS |
|
| |||
| Fasting Glucose (mg/dL) | −5.50 (−12.0, 5.00) | −2.50 (−8.00, 5.00) | NS |
|
| |||
| HbA1c (%) | −0.200 (−0.900, 0.300) | 0.000 (−0.400, 0.300) | NS |
|
| |||
| HOMA IR index | −0.687 (−3.98, 5.36) | −0.118 (−3.18, 3.40) | NS |
|
| |||
| QUICKI | 0.010 (−0.029, 0.072) | 0.001 (−0.030, 0.040) | NS |
DEXA, dual-energy X-ray absorptiometry; MRI, magnetic resonance imaging; HOMA IR, homeostasis model assessment for insulin resistance; HbA1c, glycated hemoglobin; QUICKI, quantitative insulin sensitivity check index; NS, not significant